Pfizer sees COVID-19 vaccine, therapeutic sales topping $50 billion in 2022

Pfizer CEO Albert Bourla speaks during a ceremony in Thessaloniki, GREECE, on Oct. 12, 2021. (AP Photo/Giannis Papanikos, File).

READ THE ORIGINAL POST AT www.timesofisrael.com